中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
22期
2217-2219
,共3页
淫羊藿黄酮%子宫内膜异位症%更年期综合征%子宫内膜厚度%血清雌二醇
淫羊藿黃酮%子宮內膜異位癥%更年期綜閤徵%子宮內膜厚度%血清雌二醇
음양곽황동%자궁내막이위증%경년기종합정%자궁내막후도%혈청자이순
epimedium flavones%endometriosis%climacteric syndrome%endometrial thickness%serum estradiol
目的 探讨淫羊藿黄酮植物激素治疗药物卵巢去势引起的更年期综合征的临床疗效及安全性. 方法 98例子宫内膜异位症患者随机分为对照组50例和试验组48例. 2组患者于术后第1次月经来潮日皮下注射戈舍瑞林3.6 mg, 28 d为1个周期,连续4个周期. 21 d后,对照组口服维生素E 100 mg,每天1次,连续应用112 d;试验组给予淫羊藿黄酮10 mg·kg-1·d-1 ,连续应用112 d.观察2组患者治疗期间Kupperman绝经指数变化情况、子宫内膜厚度、血清雌二醇水平及不良反应发生情况.结果 2组患者治疗1个周期后Kupperman绝经指数均明显上升,对照组显著高于试验组(均P<0.05 ). 对照组和试验组治疗前子宫内膜厚度为(3.21 ±0.55),(3.19 ±0.47)mm,治疗后为(3.11 ±0.49), (3.23 ±0.51) mm,差异无统计学意义(P>0.05).2组患者治疗前后血清雌二醇水平差异均无统计学意义(P>0.05).2组患者用药期间均无子宫内膜异位症复发,且无明显阴道出血及其他不良反应发生. 结论 淫羊藿黄酮植物激素可显著改善药物卵巢去势后引起的雌激素水平低下而出现的更年期症状,且无明显不良反应发生.
目的 探討淫羊藿黃酮植物激素治療藥物卵巢去勢引起的更年期綜閤徵的臨床療效及安全性. 方法 98例子宮內膜異位癥患者隨機分為對照組50例和試驗組48例. 2組患者于術後第1次月經來潮日皮下註射戈捨瑞林3.6 mg, 28 d為1箇週期,連續4箇週期. 21 d後,對照組口服維生素E 100 mg,每天1次,連續應用112 d;試驗組給予淫羊藿黃酮10 mg·kg-1·d-1 ,連續應用112 d.觀察2組患者治療期間Kupperman絕經指數變化情況、子宮內膜厚度、血清雌二醇水平及不良反應髮生情況.結果 2組患者治療1箇週期後Kupperman絕經指數均明顯上升,對照組顯著高于試驗組(均P<0.05 ). 對照組和試驗組治療前子宮內膜厚度為(3.21 ±0.55),(3.19 ±0.47)mm,治療後為(3.11 ±0.49), (3.23 ±0.51) mm,差異無統計學意義(P>0.05).2組患者治療前後血清雌二醇水平差異均無統計學意義(P>0.05).2組患者用藥期間均無子宮內膜異位癥複髮,且無明顯陰道齣血及其他不良反應髮生. 結論 淫羊藿黃酮植物激素可顯著改善藥物卵巢去勢後引起的雌激素水平低下而齣現的更年期癥狀,且無明顯不良反應髮生.
목적 탐토음양곽황동식물격소치료약물란소거세인기적경년기종합정적림상료효급안전성. 방법 98례자궁내막이위증환자수궤분위대조조50례화시험조48례. 2조환자우술후제1차월경래조일피하주사과사서림3.6 mg, 28 d위1개주기,련속4개주기. 21 d후,대조조구복유생소E 100 mg,매천1차,련속응용112 d;시험조급여음양곽황동10 mg·kg-1·d-1 ,련속응용112 d.관찰2조환자치료기간Kupperman절경지수변화정황、자궁내막후도、혈청자이순수평급불량반응발생정황.결과 2조환자치료1개주기후Kupperman절경지수균명현상승,대조조현저고우시험조(균P<0.05 ). 대조조화시험조치료전자궁내막후도위(3.21 ±0.55),(3.19 ±0.47)mm,치료후위(3.11 ±0.49), (3.23 ±0.51) mm,차이무통계학의의(P>0.05).2조환자치료전후혈청자이순수평차이균무통계학의의(P>0.05).2조환자용약기간균무자궁내막이위증복발,차무명현음도출혈급기타불량반응발생. 결론 음양곽황동식물격소가현저개선약물란소거세후인기적자격소수평저하이출현적경년기증상,차무명현불량반응발생.
Objective To assess the clinical efficacy and safety of epi-medium total flavones in the treatment of postmenopausal syndromes in-duced by ovarian castration. Methods The included 98 cases with ovarian endometrioma were randomly divided into control group ( n=50 ) and treatment group ( n=48).All the patients were treated with gosere-lin 3.6 mg subcutaneous injection, 28 d a cycle, treated for 4 cycles. After administering the goserelin 21 d, patients in control group were treated with vitamin E 100 mg, qd, orally for 112 d.And patients in treatment group were treated with epimedium flavones 10 mg·kg-1·d-1 , po, bid, for 112 days. The Kupperma score, endometrial thickness, serum estradiol level and adverse reactions were evaluated between the two groups.Results The Kupperma score was significantly increased in two groups after treatment, and control group significantly higher than that in treatment group ( P<0.05).The endometrial thickness of control group and treatment group before treatment were ( 3.21 ±0.55 ) , (3.19 ±0.47) mm, without significant difference with those after treat-ment, which were (3.11 ±0.49), (3.23 ±0.51) mm (P>0.05).The level of serum estradiol had no statistically changed in the control and treatment group ( P>0.05).In the period of treatment, no recurrence of endometriosis and other toxicities was found in both groups.Conclusion Epimedium flavones can improve the symptom of climacteric syndrome without significant adverse reactions.
